Medicare Advantage Authorization in Dermatology

Traditional Medicare Part B rarely requires prior authorization for standard in-office dermatology services, relying instead on Local Coverage Determinations (LCDs) and post-payment review. Medicare Advantage (MA) plans, operating under commercial payer administration, frequently impose front-end prior authorization, step therapy, and pre-service notification requirements that traditional Medicare does not mandate. When dermatology practices treat Medicare Advantage patients under the assumption that traditional Part B rules apply, the result is unexpected technical denials, delayed treatments, and uncollectible balances.

Understanding where MA plans diverge from Fee-For-Service (FFS) Medicare is critical for protecting practice revenue and preventing care delays for vulnerable patients.

Key Areas Where Medicare Advantage Imposes Additional Authorization

Medicare Advantage organizations are required by CMS to cover all Part A and Part B benefits. However, CMS allows MA plans to use utilization management tools, including prior authorization and clinical reviews, to control costs and determine medical necessity. In dermatology, these commercial utilization tools create substantial administrative friction across several service categories.

Mohs Micrographic Surgery and Advanced Reconstructions

Under traditional Medicare, Mohs surgery (CPT 96112–96115) is covered when it meets the criteria outlined in your Medicare Administrative Contractor’s (MAC) LCD, typically aligned with the American Academy of Dermatology’s Appropriate Use Criteria (AUC). Authorization is not requested in advance; the practice bills the claim with appropriate pathology and diagnosis codes, maintaining documentation in the medical record.

Conversely, many MA plans require formal prior authorization for Mohs surgery, particularly when scheduled in ambulatory surgery centers (ASCs) or when specific anatomical sites (such as trunk or extremities) are involved. Furthermore, extensive reconstructions—such as adjacent tissue transfers (CPT 14000–14061) or full-thickness skin grafts (CPT 15200–15261)—performed on the same day as Mohs may trigger separate authorization requirements or secondary medical necessity reviews before the claim will adjudicate.

Biologics and In-Office Injectables

While Part D covers most self-administered biologics, in-office systemic therapies and provider-administered biologics billed under Part B encounter aggressive step therapy rules within MA plans. Although CMS allows MA plans to apply step therapy only to Part B drugs within strict guardrails, commercial carriers frequently enforce:

• Mandatory trial and failure of conventional systemic agents (such as methotrexate, cyclosporine, or acitretin) before approving interleukin inhibitors or TNF blockers.
• Mandatory switching to preferred biosimilar agents.
• Re-authorization requirements at six- or twelve-month intervals with mandatory clinical scoring (e.g., PASI or BSA percentages) documented in the chart.

Traditional Part B does not require step therapy through conventional systemics if the provider documents clinical contraindications, whereas an MA plan will issue an outright denial without explicit formulary exception paperwork.

Phototherapy and Excimer Laser

Traditional Medicare covers narrowband UVB, PUVA, and excimer laser therapies based on documented diagnosis codes (e.g., severe plaque psoriasis, vitiligo, cutaneous T-cell lymphoma) and failure of topical therapies, monitored through treatment logs.

MA plans routinely categorize phototherapy (CPT 96900, 96910) and targeted phototherapy/excimer laser (CPT 96920–96922) under specialty pre-authorization protocols. Payers often demand:

• Initial authorization for a finite number of treatment sessions (e.g., 30 sessions over a 90-day window).
• Formal progress notes demonstrating measurable disease clearance before approving additional treatment blocks.
• Detailed photographic evidence showing baseline BSA involvement prior to initiating therapy.

Benign and Premalignant Lesion Destructions

While MAC LCDs govern the frequency and medical necessity for destroying actinic keratoses (CPT 17000, 17003, 17004) or removing symptomatic benign lesions (CPT 17110, 11200), some MA plans institute pre-payment edits or requiring prior notifications if a patient exceeds a specific lesion threshold within a calendar year. If an MA plan uses a specialty capitation or delegated risk network, routine destructions may be denied unless referred directly by the patient’s designated primary care physician (PCP).

Navigating the Legal and Regulatory Shift: CMS-4201-F

CMS published final rule CMS-4201-F to rein in excessive MA utilization management. Under these rules, MA plans must ensure their clinical coverage criteria are no more restrictive than traditional Medicare LCDs and National Coverage Determinations (NCDs). When no NCD or LCD exists, MA plans may use internal clinical criteria, provided those criteria are publicly accessible and supported by documented clinical evidence.

Additionally, the rule stipulates that prior authorizations for an ongoing course of treatment must remain valid for the entire approved duration, regardless of mid-treatment policy changes. However, enforcement remains uneven at the operational level. Payers continue to require prior authorization even when their approval criteria theoretically mirror MAC LCDs, creating an administrative barrier that can derail practice cash flow if not systematically tracked.

For practices looking to streamline workflows across complex commercial and managed Medicare policies, reviewing your end-to-end dermatology insurance billing and revenue cycle processes will reveal where unauthorized claims are slipping through.

Immediate Workflow and Documentation Controls for Dermatology Practices

To prevent denials stemming from unauthorized MA services, practices must establish clear front-end workflows that isolate MA patients from traditional Medicare Part B accounts.

1. Front-End Payer Classification

Ensure your front-desk and intake staff do not categorize Medicare Advantage plans as "Medicare" in your practice management system. Label them distinctly by carrier (e.g., "Aetna Medicare Advantage," "Humana Gold Plus," "UHC MA Choice"). Traditional Medicare rules must never apply to these accounts during insurance verification.

2. Standardized MA Pre-Service Checklist

Before performing any scheduled surgical procedure (Mohs, excisions >2cm, repairs, flaps, grafts), laser treatment, or phototherapy series:

• Check the payer portal specifically for authorization rules tied to the exact CPT code and diagnosis code.
• Confirm whether the patient's plan is an HMO requiring an electronic PCP referral in addition to prior authorization.
• Verify whether the rendering clinician is contracted directly or through a delegated Independent Practice Association (IPA).

3. Objective Medical Record Documentation

MA review nurses look for discrete, quantifiable data points rather than narrative summaries. For procedural and medical necessity reviews, clinical notes must explicitly document:

• Lesion characteristics: Exact anatomical location, size (including margins for excisions), physical appearance, and functional impairment.
• Prior treatment history: Specific dates, durations, dosages, and documented clinical failures or adverse reactions to topical steroids, calcineurin inhibitors, or cryotherapy.
• High-resolution clinical photography: Clear, dated photographs demonstrating the lesion or disease distribution, especially for phototherapy, excimer laser, and reconstructive procedures.

4. Direct Authorization Appeals Strategy

When an MA plan denies a claim or prior authorization for a service that is covered under the local MAC LCD, initiate an immediate appeal referencing CMS-4201-F. Cite the applicable MAC LCD number and highlight that the MA plan’s denial violates CMS parity regulations. Maintain a payer dispute log to identify repeat offenders for practice management escalation.

Building Consistency in Managed Care Operations

Medicare Advantage enrollment continues to grow, making it impossible for dermatology practices to bypass commercial utilization management. Protecting your bottom line requires treating Medicare Advantage plans with the same rigorous authorization protocols applied to the most restrictive commercial HMOs. By establishing strict front-end verification, capturing comprehensive clinical documentation, and aggressively appealing non-compliant denials, your practice can protect clinical autonomy and revenue integrity.

If your clinic is struggling with mounting prior authorization delays, unexpected denials, or uncollected revenue on Medicare Advantage claims, our team can help identify hidden revenue leaks. Contact us today to request a free dermatology claims audit and evaluate your revenue cycle performance.